Scholarlink

Background <p>Cyclin-dependent kinase (CDK) 4/6 inhibitors in combination with endocrine therapy are the standard of care for patients with HR-positive/HER2-negative metastatic breast cancer, improving survival and preserving quality of life. They are well tolerated with predictable and manageable adverse events dominated by haematological toxicities. A few dermatological manifestations have been reported. We report a case of ribociclib-induced vitiligo-like lesions.</p> Case presentation <p>A 44-year-old woman was diagnosed with HR+ /HER2- metastatic breast cancer, for which she was treated with ribociclib, a letrozole and LHRH agonist. Twelve months later, she developed hypopigmented lesions involving both hands and face, which were described as vitiligo-like lesions.</p> Conclusion <p>This case highlights the rare and unusual nature of this cutaneous adverse event. Emerging data and the importance of establishing appropriate therapeutic guidelines so as not to condemn an effective and well-tolerated treatment.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Vitiligo-Like Lesions Induced by Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib: A Case Report and Literature Review

  • 期刊论文

  • 发表日期：

    2025年4月20日

查看全文
  • Choukri Elm’hadi,
  • Meryem Zerrik,
  • Youssef Zemmez,
  • Rachid Tanz

摘要

Background

Cyclin-dependent kinase (CDK) 4/6 inhibitors in combination with endocrine therapy are the standard of care for patients with HR-positive/HER2-negative metastatic breast cancer, improving survival and preserving quality of life. They are well tolerated with predictable and manageable adverse events dominated by haematological toxicities. A few dermatological manifestations have been reported. We report a case of ribociclib-induced vitiligo-like lesions.

Case presentation

A 44-year-old woman was diagnosed with HR+ /HER2- metastatic breast cancer, for which she was treated with ribociclib, a letrozole and LHRH agonist. Twelve months later, she developed hypopigmented lesions involving both hands and face, which were described as vitiligo-like lesions.

Conclusion

This case highlights the rare and unusual nature of this cutaneous adverse event. Emerging data and the importance of establishing appropriate therapeutic guidelines so as not to condemn an effective and well-tolerated treatment.